Results 41 to 50 of about 4,014 (178)

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.

, 2018
In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and ...
Pineda, Juan A, Casado, Marta, Calleja, Jose Luis, Rivero, Antonio, McNabb, Brian, Subramanian, G Mani, Esteban, Rafael, Stamm, Luisa M, Buti, Maria, Rodriguez, Manuel, Pascasio-Acevedo, Juan Manuel, Morillas, Rosa Maria, Carrion, Jose Antonio, Riveiro-Barciela, Mar, Camus, Gregory, Brainard, Diana M, Morano-Amado, Luis Enrique, Andrade, Raul J, Zhang, Gulan, Forns, Xavier, Turnes, Juan, Lens, Sabela   +21 more
core   +2 more sources

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

Efectividad del tratamiento de la hepatitis C en pacientes atendidos en la consulta de atención farmacéutica

Ars Pharmaceutica, 2020
RESUMEN Objetivos: Determinar la efectividad del tratamiento de la hepatitis C crónica definida como la respuesta viral sostenida a las 12 semanas (RVS12) tras la finalización del tratamiento con fármacos antivirales de acción directa (AAD ...
José Miguel Sotoca-Momblona, Montserrat Rodriguez-Reyes, Neus Pagès-Puigdemont, Concepció Bartres-Viñas, Sergio Rodriguez-Tajes, Sabela Lens-García, Zoe Mariño-Mendez   +6 more
doaj   +1 more source

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Young-A Heo and Emma Deeks are salaried employees of Adis/Springer, are responsible for the article content and ...
Young-A Heo (4077493), Emma D. Deeks (4985339)   +1 more
core   +1 more source

TDM-guided Crushed Sofosbuvir-velpatasvir Treatment: A case study

, 2020
International audienceIn this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg).
Charlotte Pronier, Verdier, Marie-Clémence, Tron, Camille, Guyader, Dominique, Caroline Jézéquel, Pronier, Charlotte, Florian Lemaitre, Mercerolle, Marion, Camille Tron, Lalanne, Sébastien, Dominique Guyader, Lemaitre, Florian, Jezequel, Caroline, Sébastien Lalanne, Marion Mercerolle, Marie-Clémence Verdier   +15 more
core   +1 more source

Curing of chronic hepatitis C combined with coronavirus disease 2019 in a couple over 85 years old: a case series study

Frontiers in Microbiology
IntroductionData on the management of patients aged more than 85 years with chronic hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequential infections are lacking.MethodsThe current study described the ...
Qing-Lei Zeng, Xue-Yan Lv, Ru-Yue Chen, Ya-Jie Pan   +3 more
doaj   +1 more source

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

, 2015
As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.
Doehle, Brian, Schiff, Eugene, Fried, Michael, Bzowej, Natalie, An, Di, Curry, Michael P, Teperman, Lewis, Flamm, Steven L, McHutchison, John G, O'Leary, Jacqueline G, Fontana, Robert, Brown, Jr, Robert S, Fenkel, Jonathan M, Schiano, Thomas, Brainard, Diana M, Lawitz, Eric, ASTRAL-4 Investigators, Muir, Andrew J, Korenblat, Kevin M, McNally, John, Reddy, K Rajender, Osinusi, Anu, Charlton, Michael   +22 more
core   +1 more source

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis [PDF]

, 2019
[Background & Aims] Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not ...
Agarwal, Kosh, Ben-Ari, Ziv, Lurie, Yoav, Cramp, Matthew E., Markova, Svetlana, Bruck, Rafael, Osinusi, Anu O, Calleja, José Luis, Fernández-Rodríguez, Conrado M., Ampuero, Javier, Gane, Edward J., Borgia, Sergio M, Rodriguez, Conrado Fernandez, Haider, Shariq, Willems, Bernard, Cooper, Curtis, Yoshida, Eric M, Borgia, Sergio M., Dvory-Sobol, Hadas, Brown, Ashley, Hyland, Robert, Shafran, Stephen D, Cramp, Matthew E, Esteban, Rafael, Osinusi, Anu O., Ryder, Stephen D., Gane, Edward J, Kirby, Brian J, Lu, Sophia, Fox, Raymond, Meng, Amy, Dearden, Janet, Kirby, Brian J., Shaw, David, Yoshida, Eric M., Ryder, Stephen D, Shafran, Stephen D., Foxton, Matthew   +37 more
core   +1 more source

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks

Journal of Virology
The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The efficacy of SOF+GLE/PIB+RIB 16–24 weeks of treatment has been shown.
Sergii V. Fedorchenko, Zhanna Klimenko, Tatiana Martynovich, Iryna Solianyk, Tatiana Suprunenko   +4 more
doaj   +1 more source

Changes in cardiometabolic biomarkers 1 year after direct acting antiviral therapy for hepatitis C virus co‐infection among people with HIV

HIV Medicine, EarlyView.
Abstract Objectives Among people with HIV with hepatitis C virus (HCV) co‐infection, we examined differences in haemoglobin A1c (HbA1c), total cholesterol (TC), low‐density lipoprotein (LDL), high‐density lipoprotein (HDL) and atherosclerotic cardiovascular disease (ASCVD) risk score at 12‐months following direct acting antiviral (DAA) initiation ...
Raynell Lang, Elizabeth Humes, Asya Lyass, Leila H. Borowsky, Brenna Hogan, Arthur Y. Kim, Michael LaValley, Jennifer O. Lam, Ditipriya Bhar, Richard D. Moore, Frank Palella, Heidi Crane, Michael Horberg, Sonia Napravnik, Virginia A. Triant, Keri N. Althoff, on behalf of the North American AIDS Cohort Collaboration on Research and Design (NA‐ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA)   +16 more
wiley   +1 more source